There is a sentence that many people in the Pharma Market may not want to hear:
AI is not failing because the technology is weak.
AI is often failing because it is being placed on top of processes that were already broken.
This is especially true in clinical development.
Many organizations want AI to accelerate clinical trials, reduce cost, improve recruitment, optimize site selection, support medical writing, predict risks and create smarter dashboards.
But here is the uncomfortable question:
Have these organizations redesigned the processes that AI is supposed to improve?
Because AI does not magically create value in a fragmented operating model.
If study teams still work across disconnected systems, manual trackers, inconsistent data standards, unclear decision rights, late escalations and SOPs designed for a pre-digital world, AI will probably deliver limited value.
It may generate summaries.
It may draft emails.
It may create meeting notes.
It may help produce slides.
But it will not transform clinical execution.
And that is the point.
The Pharma Market does not need more AI theater.
It needs AI-enabled process transformation.
There are two major barriers that deserve more honest discussion.
The first barrier is individual.
Many professionals in the Pharma Market still underestimate how important AI literacy will become.
Some see AI as hype.
Some see it as a threat.
Some believe it is only relevant for data scientists, IT teams or innovation departments.
Some are waiting for the company to train them.
Some are quietly resisting because learning new tools exposes an uncomfortable truth: expertise alone may no longer be enough.
This does not mean that clinical operations professionals, project managers, CRAs, data managers, medical writers, regulatory specialists or vendor managers will be replaced by AI.
But it does mean something else:
Professionals who understand how to use AI responsibly may replace professionals who refuse to learn how to work with it.
The future clinical leader will not only know GCP, timelines, vendors, risks and protocol execution.
The future clinical leader will also know how to ask better questions of data.
How to challenge AI outputs.
How to detect hallucinations.
How to protect patient confidentiality.
How to use AI without compromising quality.
How to separate automation from accountability.
How to redesign workflows instead of simply digitizing old inefficiencies.
This is a new form of professional literacy.
Ignoring it is risky.
The second barrier is organizational.
AI forces companies to look in the mirror.
And sometimes the mirror is uncomfortable.
To implement AI with real impact, companies need to ask questions that go far beyond technology:
Are our clinical data structured and accessible?
Are our systems integrated?
Do our SOPs allow intelligent automation?
Do we know which decisions are repetitive, evidence-based and suitable for AI support?
Do we have governance for model validation, risk classification and human oversight?
Do we have clear accountability when AI supports a clinical or operational decision?
Do we measure cycle time, rework, quality, predictability and decision latency?
Do we know where our processes actually lose time?
Without these answers, AI becomes another layer of complexity.
A chatbot connected to a broken process is still a broken process.
A predictive dashboard fed by poor-quality data is still poor decision support.
An AI tool deployed without governance is not innovation. It is risk.
This is why the AI conversation in the Pharma Market needs to mature.
The question is no longer:
“Which AI tool should we buy?”
The better question is:
“Which process do we need to redesign so AI can create measurable value?”
In clinical development, this could mean redesigning protocol review to reduce preventable amendments.
Redesigning feasibility to combine historical site performance, epidemiology and operational capacity.
Redesigning study start-up to reduce manual handoffs.
Redesigning monitoring to prioritize risk signals instead of routine activity.
Redesigning medical writing so experts review, challenge and refine AI-generated drafts instead of starting from zero.
Redesigning project oversight so study leaders see risks earlier, not after the timeline has already slipped.
The organizations that win will not be the ones with the most AI pilots.
They will be the ones that connect AI to business-critical workflows.
They will define measurable outcomes.
They will train people.
They will clean data.
They will update SOPs.
They will implement human-in-the-loop governance.
They will decide where automation is acceptable and where expert judgment remains non-negotiable.
And they will understand that AI adoption is not only a technology program.
It is a change management program.
A process redesign program.
A leadership program.
A workforce capability program.
A quality and governance program.
The Pharma Market is already under pressure: rising R&D costs, complex protocols, recruitment delays, growing data volume, regulatory expectations, fragmented vendors and increasing demand for speed.
AI can help.
But only if we stop treating it as a shortcut.
AI is not a shortcut.
AI is a multiplier.
If the process is strong, AI may multiply speed, quality and insight.
If the process is weak, AI may multiply confusion.
So maybe the most important question for pharma companies and CROs is not:
“Are we ready for AI?”
Maybe the real question is:
“Are our processes ready to deserve AI?”
Originally published on LinkedIn on June 15, 2026.
Leave a Reply